Acadia Pharma Names New Directors, Updates Exec Pay
Ticker: ACAD · Form: 8-K · Filed: 2024-11-20T00:00:00.000Z
Sentiment: neutral
Topics: governance, executive-compensation, board-of-directors
Related Tickers: ACAD
TL;DR
Acadia Pharma adds 2 directors, updates CEO/CFO pay packages.
AI Summary
Acadia Pharmaceuticals Inc. announced on November 18, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Jeffrey L. Cummings and Ms. Sarah E. Empey, to its Board of Directors. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Ms. Brenda J. Cooper, and Chief Financial Officer, Mr. Michael R. Yang, detailing their compensation packages.
Why It Matters
The election of new directors and updates to executive compensation can signal strategic shifts or governance changes within the company, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance changes and executive compensation adjustments, which typically carry low inherent risk.
Key Players & Entities
- Acadia Pharmaceuticals Inc. (company) — Registrant
- Dr. Jeffrey L. Cummings (person) — Newly Elected Director
- Ms. Sarah E. Empey (person) — Newly Elected Director
- Ms. Brenda J. Cooper (person) — Chief Executive Officer
- Mr. Michael R. Yang (person) — Chief Financial Officer
- November 18, 2024 (date) — Date of earliest event reported
FAQ
Who were the new directors elected to Acadia Pharmaceuticals Inc.'s Board of Directors?
Dr. Jeffrey L. Cummings and Ms. Sarah E. Empey were elected as new directors.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is November 18, 2024.
Which executive officers entered into new employment agreements?
Ms. Brenda J. Cooper, the Chief Executive Officer, and Mr. Michael R. Yang, the Chief Financial Officer, entered into new employment agreements.
What is the principal executive office address for Acadia Pharmaceuticals Inc.?
The principal executive office address is 12830 El Camino Real, Suite 400, San Diego, California, 92130.
What is the SIC code for Acadia Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Acadia Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 490 words · 2 min read · ~2 pages · Grade level 13.2 · Accepted 2024-11-20 16:30:52
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ACAD The Nasdaq Stock Mar
Filing Documents
- d98060d8k.htm (8-K) — 23KB
- 0001193125-24-262556.txt ( ) — 141KB
- acad-20241118.xsd (EX-101.SCH) — 3KB
- acad-20241118_lab.xml (EX-101.LAB) — 18KB
- acad-20241118_pre.xml (EX-101.PRE) — 11KB
- d98060d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acadia Pharmaceuticals Inc. Date: November 20, 2024 By: /s/ Jennifer J. Rhodes Jennifer J. Rhodes Executive Vice President, Chief Legal Officer & Secretary